Nieuws

First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study Study by Erasmus MC marks first clinical development milestone for ISA104 immunotherapeutic treatment of chronic hepatitis B infection Oegstgeest, The Netherlands, 31 August 2023 – ISA Pharmaceuticals B.V., a clinical-stage biotech company developing immunotherapies to treat cancers and serious infectious diseases, is pleased to announce that the first patient has been dosed in the HEB-PEP study. This first-in-human (FIH) phase 1 study investigates the use of ISA104, a novel